Search Results for: Raccomandazioni cliniche per il melanoma cutaneo

Tra le raccomandazioni, aprire spesso le finestre e non fumare

Previsto il placement presso strutture attive nel settore socio-sanitario, inclusi ospedali, cliniche ed Rsa

In Reply We appreciate the thoughtful response by Akama-Garren and Hartman regarding ways of reducing fear of cancer recurrence (FCR) among patients with localized melanoma. They proposed 2 potential solutions: (1) psychological support (which we also proposed) and (2) changing terminology to recategorize melanoma in situ as melanocytic lesions with low risk of progression. In this reply, we discuss both proposals.

To the Editor Mahama et al administered a qualitative survey to assess the fear of cancer recurrence for 51 survivors of localized cutaneous melanoma. The authors found that despite good prognoses, approximately 75% of survivors had fear of cancer recurrence that was negatively associated with their psychological well-being, which, as noted by the authors, aligned with prior studies among patients with melanoma. Surprisingly, Mahama et al observed similar levels of clinical fear of cancer recurrence in patients with stage 0 and stage I to IIA localized cutaneous melanoma despite the fact that patients with stage 0 have a prognosis approaching 100% 5-year melanoma-specific survival. A systematic review of 46 studies found that 82% of survivors of thyroid cancer scored 13 or higher on the Fear of Cancer Recurrence Inventory (FCRI), suggesting that patients with melanoma and thyroid cancer share high levels of cancer worry despite relatively high survival rates compared with other cancers.

In this issue of JAMA Dermatology, Rezaei et al examine the prevalence of skin conditions and sun-related behaviors among US veterans compared with nonveterans in population-based cross-sectional data from the National Health and Nutrition Examination Survey (NHANES) from 1999 to 2018. The authors report increased prevalence of sunburn and significantly increased prevalence odds of being diagnosed with any skin cancer (72%) and melanoma (127%) in veterans. These findings highlight the need to investigate increased skin cancer risk in veterans and devise preventive interventions targeted to this population.

Con nivolumab più ipilimumab. Dieci anni fa il tasso di sopravvivenza era al 25% dopo un anno

“Gestione non sta creando criticità cliniche né nella sanità”

Le raccomandazioni dei neurologi: “Una malattia non inevitabile”